James Leggate is an government news correspondent at ENR. He has reported on a variety of issues for more than 10 years and his work has contributed to several regional Associated Press Media Editors and Murrow award wins.
Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new production facility in Odense, Denmark.
This large and complex expansion of a biologic medicine manufacturing plant increased capacity 75% by adding three production bioreactors, each 15,400 liters, as well as associated seed reactors and expanded warehouse cold rooms, freezers and central utilities.